for Incivek within 6 months as more effective and easier drugs appear.
and if someone comes out with a better/cheaper CF drug, VRTX will see 25 really soon.
And if someone looks at the competitive landscape, they know that is not going to happen for a good 6 to 8 years (translate 30 + billion in revenue) if at all with the 2nd and 3rd generation correctors.
Sentiment: Strong Buy
That is already factored in to the current price of the stock. Nothing new here.